1 |
<p align="center"><b>PLIVA Receives a License from BAYER AG for a New Chemical |
2 |
Entity for the Treatment of Fungal Infections</b></p> |
3 |
<p> PLIVA d.d. ('PLIVA') announced today that it has received a license for a |
4 |
new chemical entity for the treatment of fungal infections from BAYER AG, Germany, |
5 |
a compound in its final stage of pre-clinical trials.</p> |
6 |
<p> The compound BAY 10-8888, part of the family of beta-amino acids, was identified |
7 |
at Bayer during an effort to find novel treatment options for fungal infections |
8 |
caused by the Candida yeast. Candida infections are prevalent in patients suffering |
9 |
from AIDS or those undergoing cancer chemotherapy and/or immunosuppressive therapy |
10 |
treatment e.g. for organ transplantation and vaginal mycosis. Furthermore, Candida |
11 |
has been identified as the fourth most common pathogen in nosocomial infections |
12 |
in hospitalized patients. </p> |
13 |
<p>The total market size for anti-fungals amounted to USD 2.6 billion in 1999. |
14 |
Only the azole compound class, which was developed in the early 80s and now |
15 |
dominates over 60% of the market, is currently available for oral treatment |
16 |
of the aforementioned diseases,. Due to the increasing prevalence of Candida |
17 |
infections and the frequent use of azoles in treatment, however, severe resistance |
18 |
problems have arisen in recent years.</p> |
19 |
<p> The compound BAY 10-8888 displays high activity both in vitro and in vivo |
20 |
against Candida infections. Due to its novel mode of action, the compound additionally |
21 |
combats azole resistant pathogens. According to the data generated in various |
22 |
species, the compound exerts highly favorable pharmacokinetic behavior, indicating |
23 |
a single daily dose for patients. The compound would be the first novel class |
24 |
for the oral treatment of yeast infections following the introduction of azoles |
25 |
in the 70s. </p> |
26 |
<p>Due to a shift in its business strategy, BAYER decided to leave the anti-fungal |
27 |
segment and make the compound available for licensing. In its licensing agreement |
28 |
with BAYER, PLIVA received worldwide development and marketing rights to the |
29 |
product under non-disclosed terms.</p> |
30 |
<p> "PLIVA continues to undertake strong steps in an effort to further expand |
31 |
its position in the anti-infective business area," comments Mr. Radan Spaventi, |
32 |
Chief Scientific Officer of PLIVA. "In addition to our successful in-house research |
33 |
efforts in anti-bacterials, BAY 10-8888 will allow us to further broaden our |
34 |
product portfolio in anti-infectives. We believe that this product will represent |
35 |
a significant contribution to the anti-fungal market, given its activity against |
36 |
strains resistant to existing drugs." </p> |
37 |
<p>PLIVA has renamed the compound PLD-118, according to its classification scheme, |
38 |
and plans to start clinical development this year. In line with its R&D strategy, |
39 |
PLIVA intends to establish a relationship with a global partner for the development |
40 |
and marketing of the product after completion of Phase I and/or Phase II clinical |
41 |
trials. PLIVA's total R&D expenditures in 2000 are expected to reach about HRK |
42 |
330 million. </p> |
43 |
<p>For further information, please contact: </p> |
44 |
<p>Erika Kaspar<br> |
45 |
Vice President, Communications and Corporate Affairs <br> |
46 |
Tel: 385 1 6120 755<br> |
47 |
Fax: 385 1 6114 413<br> |
48 |
E-mail: <a href="mailto:erika.kaspar@pliva.hr">Erika.Kaspar@pliva.hr</a></p> |
49 |
<p> Marija Mandic <br> |
50 |
Financial Analyst<br> |
51 |
Tel: 385 1 6160 355 <br> |
52 |
Fax: 385 1 6120 634<br> |
53 |
E-mail: <a href="marija.mandic@pliva.hr">Marija.Mandic@pliva.hr</a> </p> |